Oncologix Tech

Oncologix Tech EV/FCF

Delisted·Sep 9, 2026

The EV/FCF (Enterprise Value to Free Cash Flow) of Oncologix Tech (OCLG) as of Oct 28, 2026 is -204.09. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 12.76 — a change of -1,699.51% (lower).

EV/FCF

-204.09

YoY

-1,699.51%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Oncologix Tech is 2017 -204.09 . EV/FCF (Enterprise Value to Free Cash Flow) of Oncologix Tech was 2016 12.76 . It decreases by -1,699.51% lower compared to the previous year.

The Oncologix Tech EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2014
-3.01 USD
Jan 1, 2015
-9.41 USD
Jan 1, 2016
12.76 USD
Jan 1, 2017
-204.09 USD
The Oncologix Tech EV/FCF history
YEAREV/FCFYoY
-204.09-1,699.51%
12.76-235.54%
-9.41+213.14%
-3.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

EV/FCF (Enterprise Value to Free Cash Flow) of Oncologix Tech is -204.09 in 2017.

EV/FCF (Enterprise Value to Free Cash Flow) of Oncologix Tech changed from 12.76 to -204.09, representing a -1,699.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Oncologix Tech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Oncologix Tech

All Key Metrics — Oncologix Tech